Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03573700
Recruitment Status : Recruiting
First Posted : June 29, 2018
Last Update Posted : November 9, 2018
Sponsor:
Information provided by (Responsible Party):
St. Jude Children's Research Hospital

Brief Summary:

SJCAR19 is a research study seeking to evaluate the use of chimeric antigen receptor (CAR) T cell therapy, a type of cellular therapy, for the treatment of pediatric, adolescent and young adult patients with relapsed or refractory CD19+ acute lymphoblastic leukemia (ALL). CAR therapy combines two of the body's basic disease fighters: antibodies and T Cells. For this type of therapy, peripheral (circulating) immune cells are collected and then undergo a manufacturing process to engineer them to more effectively kill cancer cells. The SJCAR19 product will be manufactured at the St. Jude Children's Research Hospital's Good Manufacturing Practice (GMP) facility.

The main purpose of this study is to determine:

  1. The largest dose of SJCAR19 that is safe to give,
  2. How long SJCAR19 cells last in the body,
  3. The side effects of SJCAR19, and
  4. Whether or not treatment with SJCAR19 is effective in treating people with refractory or relapsed ALL.

Condition or disease Intervention/treatment Phase
Acute Lymphoblastic Leukemia, in Relapse Acute Lymphoblastic Leukemia, Refractory Drug: Cyclophosphamide Drug: Fludarabine Drug: Mesna Device: CliniMACS Biological: CD19- specific CAR engineered autologous T-cells (SJCAR19 product) Phase 1 Phase 2

Detailed Description:

SJCAR19 is a Phase I/II clinical trial evaluating the use of SJCAR19 (CD19- specific CAR engineered autologous T-cells) in pediatric, adolescent and young adult patients with relapsed/ refractory CD19+ ALL. Treatment will include a single treatment course, with most patients receiving a lymphodepleting chemotherapy preparative regimen of fludarabine/ cyclophosphamide, followed by a single infusion of SJCAR19.

This protocol contains a 3-part consent process: 1) to proceed with autologous apheresis, 2) to proceed with manufacturing of the SJCAR19 product, and 3) to receive treatment with the SJCAR19 product (initially as Phase I, then proceeding to Phase II). The Phase I portion will evaluate the safety and maximum tolerated dose (MTD) of SJCAR19.

The Phase II portion will evaluate the efficacy, and provide further safety evaluation, of SJCAR19 in an expansion cohort at the MTD determined in the Phase I portion of the study. Additionally, for both the Phase I/II portions of the study there are correlative studies evaluating the biology of this treatment as well assessments into patient/caregiver experiences with undergoing this treatment.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 35 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: SJCAR19: A Phase I/II Study Evaluating SJCAR19 (CD19-Specific CAR Engineered Autologous T-Cells) in Pediatric and Young Adult Patients ≤ 21 Years of Age With Relapsed or Refractory CD19+ Acute Lymphoblastic Leukemia
Actual Study Start Date : July 24, 2018
Estimated Primary Completion Date : July 1, 2023
Estimated Study Completion Date : July 1, 2024


Arm Intervention/treatment
Experimental: SJCAR19 Therapy

Patients in both the Phase I and Phase II portion of the study will receive lymphodepleting chemotherapy (unless determined by PI that lymphodepletion is not necessary), followed by a single infusion of the patient-derived SJCAR19 cellular product. The most commonly used lymphodepleting chemotherapy regimen will consist of the agents: Fludarabine and Cyclophosphamide. They will also receive Mesna. Dosing of SJCAR19 on the Phase I study will follow a dose escalation schema, with dose changes based on dose-limiting toxicities. In the Phase II study, SJCAR19 dosing with follow the maximum tolerated dose, as determined in the Phase I portion.

Cells for infusion are prepared using the CliniMACS System.

Drug: Cyclophosphamide
Given IV
Other Name: Cytoxan

Drug: Fludarabine
Given IV
Other Name: Fludara

Drug: Mesna
Given IV
Other Name: Mesnex

Device: CliniMACS
The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest.

Biological: CD19- specific CAR engineered autologous T-cells (SJCAR19 product)
Given IV




Primary Outcome Measures :
  1. Maximum Tolerated Dose and Dose-limiting Toxicities [ Time Frame: 4 weeks post-SJCAR19 infusion ]
    The primary objectives for the Phase I study portion are to determine the maximum tolerated dose (MTD) and characterize the safety profile and dose-limiting toxicities (DLTs) of treatment with SJCAR19 in pediatric and young adult patient's ≤ 21 years of age, with relapsed or refractory CD19+ ALL.

  2. Complete Response Rate [ Time Frame: 4 weeks post-SJCAR19 infusion ]
    The primary objective for the Phase II study portion is to evaluate the complete response (CR) rates of SJCAR19 in pediatric and young adult patient's ≤ 21 years of age, with relapsed or refractory CD19+ ALL.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria for Autologous Apheresis:

  • Age ≤ 21 years old
  • CD19+ ALL with any of the following:

    • Minimal Residual Disease (MRD) ≥ 1% at end of up-front induction therapy
    • Hypodiploid (< 44 chromosomes or < 0.95 DNA index) CD19+ ALL with detectable disease at the end of up-front induction therapy
    • Increase in disease burden any time after the completion of up-front induction therapy
    • Primary refractory disease despite at least 2 cycles of an intensive chemotherapy regimen designed to induce remission
    • Refractory disease despite salvage therapy
    • 1st or greater relapse
  • Estimated life expectancy of > 12 weeks
  • Karnofsky or Lansky (age-dependent) performance score ≥ 50
  • Patients with a history of prior allogeneic hematopoietic cell transplantation [HCT] must be clinically recovered from prior HCT therapy, have no evidence of active GVHD and have not received a donor lymphocyte infusion (DLI) within the 28 days prior to apheresis
  • For females of child bearing age:

    • Not lactating with intent to breastfeed
    • Not pregnant with negative serum pregnancy test within 7 days prior to enrollment

Exclusion Criteria for Autologous Apheresis:

  • Known primary immunodeficiency
  • History of HIV infection
  • Severe intercurrent bacterial, viral or fungal infection
  • History of hypersensitivity reactions to murine protein-containing products

Eligibility Criteria for Manufacturing SJCAR19:

  • CD19+ ALL with any of the following:

    • Primary refractory disease despite at least 2 cycles of an intensive chemotherapy regimen designed to induce remission
    • Refractory disease despite salvage therapy
    • 2nd or greater relapse
    • Any relapse after allogeneic hematopoietic cell transplantation
    • 1st relapse if patient requires an allogeneic HCT as part of standard of care relapse therapy, but is found to be ineligible and/or unsuitable for HCT
  • Age: ≤ 21 years of age
  • Karnofsky or Lansky (age-dependent) performance score ≥ 50
  • Estimated life expectancy of > 12 weeks
  • Meets eligibility criteria to undergo autologous apheresis, or have previously undergone autologous apheresis

Inclusion Criteria for Treatment with SJCAR19:

  • CD19+ ALL with any of the following:

    • Primary refractory disease despite at least 2 cycles of an intensive chemotherapy regimen designed to induce remission
    • Refractory disease despite salvage therapy
    • 2nd or greater relapse
    • Any relapse after allogeneic hematopoietic cell transplantation
    • 1st relapse if patient requires an allogeneic HCT as part of standard of care relapse therapy, but is found to be ineligible and/or unsuitable for HCT for any of the following reasons:

      • Patients that do not have an available allogeneic donor (defined as at least a 7/8 HLA-matched related/unrelated donor, 5/6 HLA-matched umbilical cord donor, or 3/6 HLA-matched haploidentical donor)
      • Patients with refractory leukemia, for which allogeneic transplant is known to be less effective in the B-ALL population, and
      • Patients who are unable to receive myeloablative total body irradiation (TBI), which is included in standard transplant regimens for patients with B - ALL.
  • Detectable disease
  • Age: ≤ 21 years of age
  • Estimated life expectancy of > 8 weeks
  • Prior to planned SJCAR19 infusion, patients with a history of prior allogeneic HCT must be at least 3 months from HCT, have no evidence of active GVHD and have not received a donor lymphocyte infusion (DLI) within the 28 days prior to planned infusion
  • Adequate cardiac function defined as left ventricular ejection fraction > 40%, or shortening fraction ≥ 25%
  • EKG without evidence of clinically significant arrhythmia
  • Adequate renal function defined as creatinine clearance or radioisotope GFR ≥50 ml/min/1.73m2 (GFR ≥40 ml/min/1.73m2 if < 2 years of age)
  • Adequate pulmonary function defined as forced vital capacity (FVC) ≥ 50% of predicted value; or pulse oximetry ≥ 92% on room air if patient is unable to perform pulmonary function testing
  • Karnofsky or Lansky (age-dependent) performance score ≥ 50
  • Total Bilirubin ≤ 3 times the upper limit of normal for age, except in subjects with Gilbert's syndrome
  • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 5 times the upper limit of normal for age
  • Hemoglobin > 8 g/dl (can be transfused)
  • Platelet count > 20,000/μL (can be transfused)
  • Has recovered from all NCI CTAE grade III-IV, non-hematologic acute toxicities from prior therapy
  • For females of child bearing age:

    • Not lactating with intent to breastfeed
    • Not pregnant with negative serum pregnancy test within 7 days prior to enrollment
    • If sexually active, agreement to use birth control until 6 months after T-cell infusion. Male partners should use a condom
  • Available SJCAR19 product with ≥ 15% expression of the CD19-CAR, and killing of CD19+ targets ≥ 20% in an in vitro cytotoxicity assay
  • Agreement to participate in long-term follow-up on protocol NCT00695279

Exclusion Criteria for Treatment with SJCAR19:

  • CNS-3 disease with or without neurologic changes
  • CNS-1/CNS-2 disease with neurologic changes
  • Known primary immunodeficiency
  • History of HIV infection
  • Evidence of active, uncontrolled neurologic disease
  • Severe, uncontrolled bacterial, viral or fungal infection
  • History of hypersensitivity reactions to murine protein-containing products
  • Receiving systemic steroids therapy exceeding the equivalent of 0.5 mg/ kg/day of methylprednisolone, in the 7 days prior to CAR T-cell infusion
  • Receiving systemic immunosuppressive therapy in the 14 days prior to CAR T-cell infusion
  • Receiving intrathecal chemotherapy in the 7 days prior to CAR T-cell infusion

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03573700


Contacts
Layout table for location contacts
Contact: Aimee C. Talleur, MD 866-278-5833 referralinfo@stjude.org

Locations
Layout table for location information
United States, Tennessee
St. Jude Children's Research Hospital Recruiting
Memphis, Tennessee, United States, 38105
Contact: Aimee C. Talleur, MD    866-278-5833    referralinfo@stjude.org   
Principal Investigator: Aimee C. Talleur, MD         
Sponsors and Collaborators
St. Jude Children's Research Hospital
Investigators
Layout table for investigator information
Principal Investigator: Aimee C. Talleur, MD St. Jude Children's Research Hospital

Additional Information:
Layout table for additonal information
Responsible Party: St. Jude Children's Research Hospital
ClinicalTrials.gov Identifier: NCT03573700     History of Changes
Other Study ID Numbers: SJCAR19
NCI-2017-01399 ( Registry Identifier: NCI Clinical Trial Registration Proogram )
First Posted: June 29, 2018    Key Record Dates
Last Update Posted: November 9, 2018
Last Verified: November 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Pediatric Postmarket Surveillance of a Device Product: No

Keywords provided by St. Jude Children's Research Hospital:
Leukemia
Leukemia, lymphoid
Leukemia, B-cell
Relapsed
Refractory
Pediatric
Chimeric antigen receptor
CAR
CAR T cell
Anti-CD19
CD19

Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Mesna
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antimetabolites, Antineoplastic
Antimetabolites
Protective Agents